SCHEMBL30754258

SCHEMBL30754258

[2H]c1nc2ccccc2nc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.48
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
PDE10A Q9Y233 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 4/20 0.38
ALDH1A1 P00352 4/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
KDM4E B2RXH2 4/20 0.38
PKM P14618 1/20 0.38
GAA P10253 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30731286 0.76 SMN1; SMN2 (0.53) TDP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL222284 0.76 SMN1; SMN2 (0.53) TDP1MAPTSMN1; SMN2NPC1RAB9A
Hydrogen Sulfide SCHEMBL28270010 0.74 SMN1; SMN2 (0.52) TDP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL1890421 0.70 HTT (0.45) TDP1MAPTSMN1; SMN2NPC1RAB9A
Biphenyl SCHEMBL28350717 0.70 NPC1 (0.52) TDP1SMN1; SMN2NPC1RAB9APDE10A
SCHEMBL252490 0.68 ALDH1A1 (0.50) TDP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL29364243 0.68 ALDH1A1 (0.50) TDP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL31547851 0.68 ALDH1A1 (0.42) TDP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL16151415 0.67 SMN1; SMN2 (0.44) TDP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL6517140 0.67 NPC1 (0.44) TDP1MAPTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410174-B1 Small molecular inhibitors of sting signaling compositions and methods of use TYERELL IMMUNOTHERAPEUTICS INC (US) 2025-09-09 US disclosed
US-11897888-B1 Small molecular inhibitors of sting signaling compositions and methods of use STINGINN LLC (US) 2024-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410174-B1 Small molecular inhibitors of sting signaling compositions and methods of use STING1, IRF3, MAVS TDP1 741/4885MAPT 4513/4885SMN1; SMN2 4511/4885
US-11897888-B1 Small molecular inhibitors of sting signaling compositions and methods of use STING1, IRF3, MAVS TDP1 741/4885MAPT 4513/4885SMN1; SMN2 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.